TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00448734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Picoplatin
Description: The treatment regimen will be the assigned dose of picoplatin plus docetaxel, 60 mg/m2 or 75 mg/m2, once every three weeks, plus prednisone (or prednisolone, if prednisone is not available), 5 mg orally twice daily beginning on day 1 and continuing daily until therapy is discontinued.~Docetaxel will be given intravenously over 60 minutes, followed 30 minutes later by picoplatin as a 1-2 hour intravenous infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: The treatment regimen will be the assigned dose of picoplatin plus docetaxel, 60 mg/m2 or 75 mg/m2, once every three weeks, plus prednisone (or prednisolone, if prednisone is not available), 5 mg orally twice daily beginning on day 1 and continuing daily until therapy is discontinued.~Docetaxel will be given intravenously over 60 minutes, followed 30 minutes later by picoplatin as a 1-2 hour intravenous infusion.
Study: NCT02208596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pentazocine
Description: Every patient enrolled in the study will be given 15 mg pentazocine before induction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pentazocine
Description: Every patient enrolled in the study will be given 15 mg pentazocine before induction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pentazocine
Description: Every patient enrolled in the study will be given 15 mg pentazocine before induction.
Study: NCT03906396

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xbox 360 Kinect
Description: A session 30 minutes of exercise game activities using the Xbox 360 Kinect will be performed by each participant. Games uses for the activity are Sports Kinect and Sports Kinect 2. Xbox 360 Kinect - the players themselves become the ''game controller'' via their body movements and gestures, Kinect-enabled game titles lend themselves comfortably to the class of exercise games.
Study: NCT03208361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penicillin V

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Study: NCT00852969

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niacin
Description: 1000 mg tablets once per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Active Placebo
Description: 100 mg Niacin tablets once per day
Study: NCT00643136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin capsules 75 mg twice daily on Days 1-4, then 150 mg twice daily on Days 5-28

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules twice daily for 28 days
Study: NCT02208596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Study: NCT04319185

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assistance to perform Peritoneal Dialysis (PD) at home
Description: The patient receives assistance of up to one visit per day for three months depending on the patient's needs, as assessed by the interdisciplinary team, the nephrologist, and the primary investigator or delegate.
Study: NCT01495156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium treatment in combination with a SGA (Second Generation Antipsychotic)
Description: All patients will be treated with aripiprazole with a target dose of 10 mg/day and a max daily dose of 30 mg. If aripiprazole is ineffective or not tolerated, it will be tapered and risperidone treatment will be started. If patient had an adequate aripiprazole trial in the past as described above, risperidone will be the initial treatment. Risperidone dosing will begin with 0.5 mg/day on day 1 with a target dose of 2.5 mg/day and a max daily dose of 6mg.~Subjects in the lithium /adjunctive SGA group will be started at 900 mg/day lithium in thrice daily dosing. The lithium dose will be increased to 1200mg/day on day 4 if lithium has been well-tolerated and symptoms of mania remain, as determined by a phone assessment done by a blinded study physician. The target serum level of lithium will be 1.2 mEq/L (range 0.8 to 1.4 mEq/L).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo/Adjunctive SGA treatment
Description: All patients will be treated with aripiprazole with a target dose of 10 mg/day and a max daily dose of 30 mg. If aripiprazole is ineffective or not tolerated, it will be tapered and risperidone treatment will be started. If patient had an adequate aripiprazole trial in the past as described above, risperidone will be the initial treatment. Risperidone dosing will begin with 0.5 mg/day on day 1 with a target dose of 2.5 mg/day and a max daily dose of 6mg.~Subjects in the placebo /adjunctive SGA group will receive placebo for the entire trial in addition to the adjunctive SGA.
Study: NCT03246646

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching
Description: Telephone coaching was provided in a series of telephone based sessions with CSO participants

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Coaching
Description: Telephone coaching was provided in a series of telephone based sessions with CSO participants
Study: NCT02517437

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Suprascapular & axillary blocks
Description: After infiltration with 1 mL of 1% lidocaine, local anesthetics (20 mL of 0.5% ropivacaine) will then be injected in 5 mL aliquots to achieve circumferential spread around the nerve.The axillary nerve block will be performed next in the posterior aspect of the operative arm. The neurovascular bundle encompassing the humeral artery, posterior circumflex artery, and axillary nerve is visualized in the lateral edge of the quadrangular space, deep to the deltoid muscle, inferior to the teres minor muscle, and superior to the triceps tendon. After infiltration with 1 mL of 1% lidocaine, local anesthetics (20 mL of 0.5% ropivacaine) will then be injected in 5 mL aliquots after negative aspiration to achieve circumferential spread around the bundle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene block
Description: After sterile skin preparation with chlorhexidine and infiltration with 1 mL of 1% lidocaine, a 5 cm 22 G insulated needle is then inserted and local anesthetic solution (20 mL of 0.5% ropivacaine) will be injected in 5 mL aliquots after negative aspiration for blood to achieve spread posterior to or between the C5 and C6 nerve roots.
Study: NCT01914068

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised exercise in hospital
Study: NCT04253496

Intervention type: OTHER
Intervention: Tumor samples and MRI
Description: We will use DNA and RNA tumor samples. We will not use germline or blood DNA. These data will be combined with their magnetic resonance imaging (MRI) at different times: at diagnosis, at the end of treatment and at the progression of the disease.

Intervention type: OTHER
Intervention: Tumor samples and MRI
Description: We will use DNA and RNA tumor samples. We will not use germline or blood DNA. These data will be combined with their magnetic resonance imaging (MRI) at different times: at diagnosis, at the end of treatment and at the progression of the disease.
Study: NCT02784353

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perioperative rehabilitation program
Description: Perioperative rehabilitation program~* preoperative rehabilitation : 2 weeks prior to operation~* postoperative rehabilitation : 3 months after operation
Study: NCT00917397

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: trauma-focused cognitive behavioural therapy
Description: once a week
Study: NCT02784353

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: conventional perioperative management without rehabilitation program
Study: NCT02327416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Y peginterferon alfa-2b
Description: In arm 2 and 3, Y peginterferon alfa-2b is used for 96 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Y peginterferon alfa-2b
Description: In arm 2 and 3, Y peginterferon alfa-2b is used for 96 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony stimulating factor
Description: In arm 3, Granulocyte-macrophage colony stimulating factor is used for 48 weeks intermittently

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir and or adefovir dipivoxil
Description: In arm 1, Entecavir and or adefovir dipivoxil are used for 96 weeks and the follow up 24 weeks as conventional control, In arm 2 and 3, Entecavir and or adefovir dipivoxil are used for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir and or adefovir dipivoxil
Description: In arm 1, Entecavir and or adefovir dipivoxil are used for 96 weeks and the follow up 24 weeks as conventional control, In arm 2 and 3, Entecavir and or adefovir dipivoxil are used for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir and or adefovir dipivoxil
Description: In arm 1, Entecavir and or adefovir dipivoxil are used for 96 weeks and the follow up 24 weeks as conventional control, In arm 2 and 3, Entecavir and or adefovir dipivoxil are used for 48 weeks.
Study: NCT00221546

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Giving DHA-rich supplement
Description: Giving DHA-rich supplement to patients.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Giving DHA-rich supplement
Description: Giving DHA-rich supplement to patients.
Study: NCT03384186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan Modified Release Prototype 1
Description: Danicopan (400 milligrams \[mg\]) oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan Modified Release Prototype 2
Description: Danicopan (400 mg) oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan Modified Release Prototype 3
Description: Danicopan (800 mg) oral tablet.
Study: NCT01871545

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Magnetic Resonance Imaging is a radiation free non invasive technique using magnetic radiofrequency waves to image the body. In this study, the research team would like to investigate the possibility of providing functional information on aggressiveness, vascularity and oxygen uptake in liver cancer tumors.
Study: NCT03326063

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ifetroban
Description: 4-week, double-blind, placebo-controlled parallel-design trial of oral ifetroban (a TP receptor antagonist) in patients with AERD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4-week, double-blind, placebo-controlled parallel-design trial of oral ifetroban (a TP receptor antagonist) in patients with AERD
Study: NCT04237181

Intervention type: DEVICE
Group type: OTHER
Intervention: Filmarray PCR multiplex-PCT assay
Description: Filmarray PCR multiplex gastro intestinal panel on stools and serum PCT dosage
Study: NCT03843528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Vorinostat will be administered concurrent with low-dose azacitidine post-transplant, on days 1-7 and 15-21 of 28 day cycles. This is an oral medication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine Injection
Description: Azacitidine will be administered on days 1-5 of each 28 day cycle, either by IV or subcutaneous injection. The dose of azacitidine will be fixed, with no dose-escalation.
Study: NCT06443333

Intervention type: OTHER
Intervention: Data collection and follow-up observation
Description: At the time of enrollment, the patient's biological samples are collected to obtain genetic information. Following enrollment, trained investigators carry out a 2-year follow-up observation through face-to-face, telephone call or online visits. During the follow-up, basic clinical information, laboratory tests, imaging examinations, neurophysiology, clinical classification, medication use, and scale assessments are collected.

Intervention type: OTHER
Intervention: Data collection
Description: Collect demographic and genetic information from healthy volunteers upon enrollment.
Study: NCT00371540

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home visit by community care coordinators
Description: Decrease in patient visits to the clinic from the standard of once per month to every 3 months with home visits monthly.
Study: NCT04233710

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Robot Rehabilitation + tDCS
Description: Robotic therapy with Kinarm Exoskeleton Robot and 1 mA cathodal tDCS applied to contralesional M1 for 20 minutes.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Robotic Rehabilitation + sham tDCS
Description: Robotic therapy with Kinarm Exoskeleton Robot and sham tDCS.
Study: NCT03340311

Intervention type: DEVICE
Group type: OTHER
Intervention: iHealth Wireless Smart Gluco- Monitoring System (BG5)
Description: Over the course of 8 weeks, participants collected serum glucose logs (SGL) for 4 weeks using usual care followed by SGL's log for 4 weeks using Bluetooth-enabled glucometers and the iGluco application.
Study: NCT03807245

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBS-NN/NN2 with Alhydrogel® 25
Description: GBS-NN/NN2 with Alhydrogel® vaccine will administered to subjects intramuscular 2 times with 4 weeks apart

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo GBS-NN/NN2 with Alhydrogel® 25
Description: GBS-NN/NN2 with Alhydrogel® vaccine will administered to subjects intramuscular 2 times with 4 weeks apart

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo GBS-NN/NN2 with Alhydrogel® 50
Description: GBS-NN/NN2 with Alhydrogel® vaccine will administered to subjects intramuscular 2 times with 4 weeks apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBS-NN/NN2 with Alhydrogel® 50
Description: GBS-NN/NN2 with Alhydrogel® vaccine will administered to subjects intramuscular 2 times with 4 weeks apart
Study: NCT02293824

Intervention type: DRUG
Intervention: Caffeine
Description: Given per standard of care.
Study: NCT00588523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide followed by high dose busulfan and thiotepa
Description: Temozolomide 200mg/m2 PO Days 1-5 recycled every 28 days Day minus -8 thiotepa 250 mg/m2 intravenously Day minus -7 thiotepa 250 mg/m2 intravenously Day minus -6 thiotepa 250 mg/m2 intravenously Day minus -5 busulfan 3.2 mg/kg intravenously over two hours Day minus -4 busulfan 3.2 mg/kg intravenously over two hours Day minus -3 busulfan 3.2 mg/kg intravenously over two hours Day minus -2 rest Day minus -1 rest Day 0 peripheral blood stem cell or bone marrow reinfusion
Study: NCT04966039

Intervention type: OTHER
Intervention: No intervention.
Description: There was no intervention.
Study: NCT01880151

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG
Description: EEG recorded during a resting condition and during an episodic memory task condition

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG
Description: EEG recorded during a resting condition and during an episodic memory task condition

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG
Description: EEG recorded during a resting condition and during an episodic memory task condition
Study: NCT02948582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate Inhalation Solution12.5μg
Description: Glycopyrrolate Inhalation Solution12.5μg via eFlow, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate Inhalation Solution 50μg
Description: Glycopyrrolate Inhalation Solution 50μg via eFlow, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate Inhalation Solution 100μg
Description: Glycopyrrolate Inhalation Solution 100μg via eFlow, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate Inhalation Solution 200μg
Description: Glycopyrrolate Inhalation Solution 200μg via eFlow, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate Inhalation Solution 400μg
Description: Glycopyrrolate Inhalation Solution 400μg via eFlow, once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 0.5mL
Description: Placebo 0.5mL via eFlow, once daily
Study: NCT04483258

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sedation with sevoflurane insufflation
Description: Induction with %8sevoflurane after adequate sedation reducing %3

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intravenous sedation
Description: midazolam +ketamine + atropine
Study: NCT00678288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Sorafenib 400 mg (two 200 mg tablets) BID PO, continuously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006) + Interferon
Description: Sorafenib 400 mg (two 200 mg tablets) BID PO, continuously. IFN alpha-2a 3MIU FIW s.c., from Monday to Friday (total weekly dose 15 MIU) s.c., to start one week after commencing sorafenib.
Study: NCT02967679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MD1003
Study: NCT02881411

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-soft tissue therapy
Description: Manual therapy for the muscles in the upper or lower limbs.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fibromyalgia coping skills programme
Description: Exercise, education programme
Study: NCT02253095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multiple Micronutrient Supplement

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03654118

Intervention type: OTHER
Intervention: Phone follow-up
Description: Through a short phone interview :~* Determination of a complication (Infection, capsulitis, recurrence)~* Determination of the Rowe score~* Determination of the Walch-Duplay score
Study: NCT03072472

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endocuff Vision
Description: The EndocuffTM (ARC Medical Design Ltd and Diagmed, UK) is a device (CE marked in UK) made of a soft plastic material with a unique dynamic shape. Endocuff Vision™ is placed snugly around the colonoscope tip prior to insertion. It does not project beyond the tip of the scope, providing an unrestricted view. It helps anchor the scope tip against the bowel wall to provide a stable platform of access. The soft, elastic projections are pushed back (recoiled) towards the scope shaft during insertion but evert during withdrawal to hold colon folds away from the field of view.
Study: NCT01934907

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Washing of packed RBC by normal saline
Study: NCT02925559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: The active treatment will include a 10 mg dose of dapagliflozin orally once a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gliclazide MR
Description: As comparator, gliclazide MR will be administered at a dose of 120 mg orally once a day.
Study: NCT06445465

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [18F]MNI-1216
Description: \[18F\]MNI-1216 is an intravenously administered radioactive imaging agent being studied as a potential positron emitting radiopharmaceutical for in vivo imaging of α-synuclein deposits.
Study: NCT03464513

Intervention type: DEVICE
Group type: OTHER
Intervention: Multislice CT Angiography
Description: Multislice CT angiography (MSCTA) provides a relatively non-invasive and effective way of localising the source of bleeding, especially in patients with continuous bleeding.
Study: NCT00730353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib malate
Description: Sunitinib malate 37.5 mg orally, daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 90 mg/m2 IV on days 1, 8 and 15.
Study: NCT04295811

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EsoGuard (lab assay)
Description: EsoGuard assay (LDT) will be used on cells collected using the EsoCheck (510K cleared esophageal cell collection device)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Esophagogastroduodenoscopy
Description: Planned EGD to diagnose and/or treat disorders of esophagus, stomach, and small intestine. When abnormal tissues are noted, biopsies of the tissue are taken through the scope to diagnose tissue abnormalities.
Study: NCT03475446

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real anodal tDCS healthy elderly
Description: A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real anodal tDCS in the group of healthy elderly.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real tACS healthy elderly
Description: A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real tACS in the group of healthy elderly.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham tES healthy elderly
Description: A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the sham tES in the group of healthy elderly.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real anodal tDCS MCI
Description: A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real anodal tDCS in the MCI group.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real tACS MCI
Description: A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real tACS in the MCI group.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham tES MCI
Description: A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the sham tES in the MCI group.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real anodal tDCS AD
Description: A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real anodal tDCS in the AD group.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real tACS AD
Description: A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real tACS in the AD group.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham tES AD
Description: A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the sham tES in the AD group.